FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
| Regeneron (NASDAQ: REGN) | Delayed: 805.89 -1.59 (0.2%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $807.48 | 52 Week High | $592.36 | |||
| Open | $806.74 | 52 Week Low | $325.35 | |||
| Day High | $813.86 | P/E | 211.52 | |||
| Day Low | $800.24 | EPS | $3.81 | |||
| Volume | 351,792 | |||||
